Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Letale Polypharmazie bei einem Hypertoniker
Jörger M, Diethelm M. Letale Polypharmazie bei einem Hypertoniker - Lethal polypharmacy in a patient with arterial hypertension. Deutsche medizinische Wochenschrift (1946) 2004; 129:2714-6.
10.12.2004Letale Polypharmazie bei einem Hypertoniker
10.12.2004Deutsche medizinische Wochenschrift (1946) 2004; 129:2714-6
Jörger Markus, Diethelm Markus
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
01.12.2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
01.12.2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
Neoadjuvant therapy with gemcitabine in breast cancer
Schneeweiss A, Bastert G, Huober J, Wallwiener D, Hamerla R, Lichter P. Neoadjuvant therapy with gemcitabine in breast cancer. Oncology (Williston Park, N.Y.) 2004; 18:27-31.
01.12.2004Neoadjuvant therapy with gemcitabine in breast cancer
01.12.2004Oncology (Williston Park, N.Y.) 2004; 18:27-31
Schneeweiss Andreas, Bastert Gunther, Huober Jens, Wallwiener Diethelm, Hamerla Rainer, Lichter Peter
Neoadjuvant endocrine therapy in primary breast cancer
Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant endocrine therapy in primary breast cancer. Clinical breast cancer 2004; 5:341-7.
01.12.2004Neoadjuvant endocrine therapy in primary breast cancer
01.12.2004Clinical breast cancer 2004; 5:341-7
Huober Jens, Krainick-Strobel Ute, Kurek Raffael, Wallwiener Diethelm
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.
29.11.2004Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
29.11.2004BJC 2004; 91:1893-901
Bernhard J, Goldhirsch A, Price K N, Fey M F, Thürlimann Beat, Veronesi A, Crivellari D, Rudenstam C-M, Snyder R, Collins J, Perey L, Forbes J F, Murray E, Castiglione-Gertsch M, Gelber R D, Coates A S, Zahrieh D, Hürny C
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H, Huober J, Bastert G. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. European journal of cancer (Oxford, England : 1990) 2004; 40:2432-8.
01.11.2004Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study
01.11.2004European journal of cancer (Oxford, England : 1990) 2004; 40:2432-8
Schneeweiss A, Wallwiener D, Hamerla R, Solomayer E, Krauss K, Beldermann F, Rudlowski C, von Fournier D, Sinn H-P, Huober Jens, Bastert G
Predicting gender differences as latent variables: summed scores, and individual item responses: a methods case study
Pietrobon R, Taylor M, Gueller U, Higgins L, Jacobs D, Carey T. Predicting gender differences as latent variables: summed scores, and individual item responses: a methods case study. Health Qual Life Outcomes 2004; 2:59.
25.10.2004Predicting gender differences as latent variables: summed scores, and individual item responses: a methods case study
25.10.2004Health Qual Life Outcomes 2004; 2:59
Pietrobon Ricardo, Taylor Marcus, Gueller Ulrich, Higgins Laurence D, Jacobs Danny O, Carey Timothy
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
Gautschi O, Stahel R, Betticher D, Jörger M, Weder W, Ratschiller D, Chassé E, Marx A, Jermann M, Huegli B, Bigosch C, Ziegler A. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64.
15.10.2004Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy
15.10.2004Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64
Gautschi Oliver, Stahel Rolf A, Betticher Daniel C, Jörger Markus, Weder Walter, Ratschiller Daniel, Chassé Eveline, Marx Arthur, Jermann Monika, Huegli Barbara, Bigosch Colette, Ziegler Annemarie
Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients
Gueller U, Jain N, Curtis L, Oertli D, Heberer M, Pietrobon R. Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients. J Am Coll Surg 2004; 199:567-75; discussion 575-7.
01.10.2004Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients
01.10.2004J Am Coll Surg 2004; 199:567-75; discussion 575-7
Gueller Ulrich, Jain Nitin, Curtis Lesley H, Oertli Daniel, Heberer Michael, Pietrobon Ricardo
Increased body mass index and ASA physical status IV are risk factors for block failure in ambulatory surgery - an analysis of 9,342 blocks
Cotter J, Nielsen K, Gueller U, Steele S, Klein S, Greengrass R, Pietrobon R. Increased body mass index and ASA physical status IV are risk factors for block failure in ambulatory surgery - an analysis of 9,342 blocks. Can J Anaesth 2004; 51:810-6.
01.10.2004Increased body mass index and ASA physical status IV are risk factors for block failure in ambulatory surgery - an analysis of 9,342 blocks
01.10.2004Can J Anaesth 2004; 51:810-6
Cotter Juliann T, Nielsen Karen C, Gueller Ulrich, Steele Susan M, Klein Stephen M, Greengrass Roy A, Pietrobon Ricardo
Therapeutic drug monitoring of non-anticancer drugs in cancer patients
Jörger M, Schellens J, Beijnen J. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods and findings in experimental and clinical pharmacology 2004; 26:531-45.
01.09.2004Therapeutic drug monitoring of non-anticancer drugs in cancer patients
01.09.2004Methods and findings in experimental and clinical pharmacology 2004; 26:531-45
Jörger Markus, Schellens J H M, Beijnen J H
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
01.09.2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
01.09.2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
Yee K, Schittenhelm M, O'Farrell A, Town A, McGreevey L, Bainbridge T, Cherrington J, Heinrich M. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104:4202-9.
10.08.2004Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
10.08.2004Blood 2004; 104:4202-9
Yee Kevin W H, Schittenhelm Marcus, O'Farrell Anne-Marie, Town Ajia R, McGreevey Laura, Bainbridge Troy, Cherrington Julie M, Heinrich Michael C
Effect of provider volume on resource utilization for surgical procedures of the knee
Jain N, Pietrobon R, Gueller U, Shankar A, Ahluwalia A, Higgins L. Effect of provider volume on resource utilization for surgical procedures of the knee. Knee Surg Sports Traumatol Arthrosc 2004; 13:302-12.
04.08.2004Effect of provider volume on resource utilization for surgical procedures of the knee
04.08.2004Knee Surg Sports Traumatol Arthrosc 2004; 13:302-12
Jain Nitin, Pietrobon Ricardo, Gueller Ulrich, Shankar Anoop, Ahluwalia Ajit S, Higgins Laurence D
[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
Prikler L, Scandella E, Men Y, Engeler D, Diener P, Gillessen Sommer S, Ludewig B, Schmid H. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. Aktuelle Urologie 2004; 35:326-30.
01.08.2004[Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]
01.08.2004Aktuelle Urologie 2004; 35:326-30
Prikler L, Scandella Elke, Men Y, Engeler Daniel, Diener P-A, Gillessen Sommer Silke, Ludewig Burkhard, Schmid H-P
Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
Mueck A, Seeger H, Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?. Life sciences 2004; 75:1205-10.
23.07.2004Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol?
23.07.2004Life sciences 2004; 75:1205-10
Mueck A O, Seeger H, Huober Jens
Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section
Krauss K, Aydeniz B, Dohmen B, Wehrmann M, Wallwiener D, Huober J. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:2966-8.
15.07.2004Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 2. Detection of an appendiceal carcinoma by whole-body positron emission tomography after Caesarean section
15.07.2004Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:2966-8
Krauss K, Aydeniz B, Dohmen B M, Wehrmann M, Wallwiener D, Huober Jens
Spätkomplikationen nach Sectio: Fallberichte zu Blutungsstörungen und isthmische Schwangerschaft bei Myometriumdehiszenz
Simmler R, Venturelli S, Pok J, Wisser J, Fehr M, Haller U, Hornung R (2004). Spätkomplikationen nach Sectio: Fallberichte zu Blutungsstörungen und isthmische Schwangerschaft bei Myometriumdehiszenz.
24.06.2004Spätkomplikationen nach Sectio: Fallberichte zu Blutungsstörungen und isthmische Schwangerschaft bei Myometriumdehiszenz
24.06.2004Jahreskongress Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) 2004
Simmler R, Venturelli S, Pok J, Wisser J, Fehr M, Haller U, Hornung René
Application of Cisplatin following Epicutan Testing in Patients with Allergy to Carboplatin. A Report of Two Cases
Zech N, Fehr M, Ballmer B, Haller U, Hornung R (2004). Application of Cisplatin following Epicutan Testing in Patients with Allergy to Carboplatin. A Report of Two Cases.
24.06.2004Application of Cisplatin following Epicutan Testing in Patients with Allergy to Carboplatin. A Report of Two Cases
24.06.2004Jahreskongress Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) 2004
Zech NH, Fehr M, Ballmer B, Haller U, Hornung René
Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases
van Swieten P, Ploegh H, van der Marel G, Driessen C, Leeuwenburgh M, Kalbacher H, Wong C, Reich M, Kessler B, van den Nieuwendijk A, Maehr R, Overkleeft H. Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases. Bioorganic & medicinal chemistry letters 2004; 14:3131-4.
21.06.2004Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases
21.06.2004Bioorganic & medicinal chemistry letters 2004; 14:3131-4
van Swieten Paul F, Ploegh Hidde L, van der Marel Gijsbert A, Driessen Christoph, Leeuwenburgh Michiel A, Kalbacher Hubert, Wong Chung-Sing, Reich Michael, Kessler Benedikt M, van den Nieuwendijk Adrianus M C H, Maehr Rene, Overkleeft Herman S